What Does VOYAGER PAD Mean for Antithrombotic Therapy?

This transcript has been edited for clarity.

Michelle L. O'Donoghue, MD, MPH: Hi. This is Dr Michelle O'Donoghue, reporting for Medscape. Unfortunately we're in the midst of the pandemic, so I will be interviewing Dr Marc Bonaca remotely through the Zoom interface. As you all know, American College of Cardiology (ACC) live scientific sessions were canceled. But one of the hottest topics being presented at the virtual ACC are the results of the VOYAGER PAD trial. I'd like to introduce Dr Marc Bonaca, who is a cardiologist as well as a vascular medicine specialist at University of Colorado. Welcome, Marc.

Marc Bonaca, MD, MPH: Thank you, Michelle. It's a pleasure to join you virtually. These are very challenging times for all of us with the pandemic, but we're very grateful to you and to the ACC for making all the science move forward through this virtual platform. Thank you.

O'Donoghue: People are really excited about this topic, I think in part because we don't have a lot of options to offer our patients who have peripheral artery disease(PAD). A lot of trials have not been done in the past, and thus far we have not had a lot of great options to turn to reliably.